Coventry-based NanoSyrinx, a synthetic biology company developing nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, has appointed Dr Edwin Moses as chairman, taking over from Stephen Taylor who has led the board since the Company’s inception.

Moses is an entrepreneur and C-level executive in the life sciences industry, with more than 30 years of board-level experience from over 20 life science companies. He is chairman of Achilles Therapeutics, LabGenius and Avantium. He was previously chief executive of Ablynx until its agreed takeover by Sanofi for $4.8 billion in 2018, and chief executive of Oxford Asymmetry International prior to its sale to Evotec for £316 million. He led both companies’ IPOs on the London Stock Exchange, EuroNext and Nasdaq.

Dr Joe Healey, chief executive of NanoSyrinx said: “Edwin has significant experience as a successful CEO and chairman, with extensive involvement in biotech fundraising, strategic commercial partnerships and successful exits. We are thrilled to have him joining as chair of our board as we drive forward with our ambitious plans. He joins us at a pivotal stage alongside this financing, which places us in a well-capitalised position to further develop our intracellular drug delivery technology to realise its full potential in developing medicines.”

Moses commented: “NanoSyrinx’s technology promises to make a tremendous positive difference to the very challenging problem of intracellular delivery of therapeutics. I am delighted to join the board and help build on the momentum of this latest fundraise, to support the company and its leadership team in the further development of this unique platform which has the potential to create enormous value and make a real difference to patients’ lives.”